The current role of neoadjuvant chemotherapy in the management of cervical carcinoma.
The role of neoadjuvant chemotherapy (NACT) in cervical cancer has been a matter of investigation over the last 20 years. A systematic review and meta-analysis of individual patient data (IPD) demonstrated that NACT followed by surgery is superior to radiotherapy alone in terms of overall survival. However, in spite of the results of the meta-analysis, NACT has not been adopted as the new standard of care. In the present paper, we review the reasons why NACT is still considered an investigational approach in cervical cancer.
González-Martín
Antonio
A
Medical Oncology Department, MD Anderson International España, Madrid, Spain. agonzalezm@seom.org
González-Cortijo
Lucía
L
Carballo
Natalia
N
Garcia
Juan F
JF
Lapuente
Fernando
F
Rojo
Alejandro
A
Chiva
Luis M
LM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D002945:Cisplatin